Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.1 - [Pfizer]

3 Nov 2015 18:01

RNS Number : 4545E
Goldman Sachs (Asia) Finance
03 November 2015
Β 

Ap9

Β 

APPENDIXΒ 3 DISCLOSUREΒ FORMS

Β 

Β Β 

FORMΒ 8.1(a)&(b)(i)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.1(a)Β ANDΒ (b)(i)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANELΒ ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ OFFERORS,Β OFFEREESΒ ORΒ PARTIES ACTINGΒ INΒ CONCERTΒ WITHΒ THEMΒ FORΒ THEMSELVESΒ ORΒ FORΒ DISCRETIONARYΒ CLIENTS

Β 

1. KEYΒ INFORMATION

Β 

Name of person dealing (Note 1)

(GS) GOLDMAN SACHS (ASIA) FINANCE

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 2)

USD ordinary

Date of dealing

02 November 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

0 (0.00)

0 (0.00)

(2) Derivatives (other than options)

0 (0.00)

0 (0.00)

(3) Options and agreements to purchase/sell

0 (0.00)

0 (0.00)

Total

0 (0.00)

0 (0.00)

Β 

Β 

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Ap10

Β 

Β 

3. DEALINGSΒ (NoteΒ 4)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Call Option

2,600

0.0000 USD

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)

Β 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap11

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

Β 

Β 

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β this shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β YES/NO

Β 

Date of disclosure

03 November 2015

Contact name

Aadithya Rao and Yiannis Bardis

Telephone number

+44(20) 7051 9046 / +44(20) 7774 7107

Name of offeree/offeror with which acting in concert

Pfizer Inc

Specify category and nature of acting in concert status

Advisor to Offeror

Ap31

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEEAXFDESXSFFF
Date   Source Headline
17th Nov 20153:32 pmRNSForm 8.3 - Pfizer Inc Amendment
17th Nov 20153:32 pmRNSForm 8.3 - Pfizer Inc
17th Nov 20153:21 pmRNSForm 8.3 - Pfizer Inc
17th Nov 20153:16 pmRNSForm 8.3 - [PFIZER INC]
17th Nov 20153:14 pmRNSForm 8.3 - Allergan plc
17th Nov 20152:56 pmBUSForm 8.3 - Pfizer Inc.
17th Nov 20152:45 pmRNSForm 8.3 - ALLERGAN PLC
17th Nov 20152:36 pmRNSForm 8.3 - PFIZER INC
17th Nov 20152:27 pmRNSForm 8.3 - Pfizer Inc.
17th Nov 20152:26 pmRNSRule 38.5 - Replacement Pfizer INC
17th Nov 20152:24 pmRNSForm 8.3 - Pfizer Inc
17th Nov 20152:23 pmRNSForm 8.3 - Allergan plc
17th Nov 20152:07 pmRNSForm 8.3 - Allergan Plc
17th Nov 201512:10 pmRNSForm 38.5a
17th Nov 201512:09 pmRNSForm 38.5b
17th Nov 201512:07 pmRNSForm 38.5b
17th Nov 201512:03 pmRNSForm 8.1 - [Pfizer Inc]
17th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
17th Nov 201511:43 amRNSForm 38.5(b) - Pfizer Inc
17th Nov 201511:16 amRNSForm 38.5(a) - Pfizer Inc
17th Nov 201510:30 amRNSRule 38.5 - Pfizer INC
17th Nov 201510:29 amRNSRule 38.5 - Pfizer INC
17th Nov 201510:28 amRNSRule 38.5 - Pfizer INC
17th Nov 20157:00 amRNSForm 8.3 - Pfizer, Inc Replacement non material
16th Nov 20154:05 pmRNSForm 8.3 - Allergan PLC
16th Nov 20153:52 pmRNSForm 8.3 - PFIZER INC
16th Nov 20153:49 pmRNSForm 8.3 - PFIZER INC.
16th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
16th Nov 20153:27 pmRNSForm 8.3 - Allergan plc
16th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
16th Nov 20153:13 pmRNSForm 8.3 - Pfizer Inc
16th Nov 20153:12 pmRNSForm 8.3 - Pfizer Inc Amendment
16th Nov 20153:05 pmRNSForm 8.3 - [PFIZER INC]
16th Nov 20153:03 pmRNSForm 8.3 - Pfizer Inc
16th Nov 20153:02 pmBUSForm 8.3 - Pfizer Inc.
16th Nov 20152:47 pmRNSForm 8.3 - Pfizer, Inc.
16th Nov 20152:41 pmRNSForm 8.3 - Pfizer Inc
16th Nov 20152:28 pmRNSForm 8.3 - Allergan Plc
16th Nov 201512:03 pmRNSForm 38.5b
16th Nov 201512:03 pmRNSForm 8.1- [Pfizer]
16th Nov 201512:03 pmRNSForm 38.5a
16th Nov 201512:01 pmRNSForm 38.5b
16th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc
16th Nov 201511:50 amRNSForm 38.5b
16th Nov 201511:49 amRNSForm 38.5(b) - Pfizer Inc
16th Nov 201511:32 amRNSForm 8.1a - Pfizer Inc
16th Nov 201511:10 amRNSRule 38.5 - Pfizer INC
16th Nov 201511:09 amRNSRule 38.5 - Pfizer INC
16th Nov 201511:09 amRNSRule 38.5 - Pfizer INC
13th Nov 20155:16 pmRNSForm 38.5(b) - Pfizer Inc. - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.